ENSYSCE BIOSCIENCES INC (ENSC)

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The company is headquartered in La Jolla, California and currently employs 7 full-time employees. The company went IPO on 2017-12-01. The firm is engaged in developing solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. The firm is using its proprietary technology platforms to develop safer prescription drugs. The firm's development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology - the Trypsin Activated Abuse Protection, (the TAAP platform), and an over-dose protection opioid prodrug technology - the Multi-Pill Abuse Resistant, (MPAR platform). The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform when combined with the Company’s TAAP prodrugs is designed not only to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences.

Company Info

ENSYSCE BIOSCIENCES INC

7946 Ivanhoe Avenue, Suite 201

La Jolla CALIFORNIA

P: 18582634196

CEO: Daniel B. Silvers

Employees: 7

Website: https://ensysce.com/